Drug Profile

SIS 201 CD

Alternative Names: SIS-201-CD

Latest Information Update: 13 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SiSaf
Developer Avellino Labs USA; SiSaf
Class Eye disorder therapies; Gene therapies; Small interfering RNA
Mechanism of Action Gene transference; RNA interference; Transforming growth factor beta1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

13 Jun 2024 Preclinical development is ongoing for Corneal-disorders in USA and United Kingdom
28 Jan 2024 No recent reports of development identified for preclinical development in Corneal-disorders in United Kingdom (Ophthalmic, Drops)
28 Jan 2024 No recent reports of development identified for preclinical development in Corneal-disorders in USA (Ophthalmic, Drops)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com